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The GOAL study: a prospective examination of the impact of
factor V Leiden and ABO(H) blood groups on haemorrhagic
and thrombotic pregnancy outcomes
Introduction
Factor V Leiden (FVL) occurs commonly in those of
European extraction and a number of studies, predominantly
case–control in design, have linked FVL with thrombosis-
associated pregnancy outcomes, such as fetal loss and pre-
eclampsia (Robertson et al, 2006). In a systematic review,
however, the risk of an adverse outcome in FVL heterozygotes
was a modest twofold (Robertson et al, 2006), a risk which
was derived mainly from retrospective case–control studies
[which can exaggerate an effect when compared with
prospective cohorts (Klerk et al, 2002)]. By contrast, the high
prevalence of FVL might also indicate an evolutionary
advantage of the mutation. One plausible effect would be
a reduction in haemorrhage, perhaps leading to protection
from iron deficiency, with such a reduced bleeding risk
already reported out-with pregnancy (van ‘t Veer et al, 1997;
Corral et al, 2001; Escuriola Ettingshausen et al, 2001;
Castoldi et al, 2003; Donahue et al, 2003; Bos et al, 2005).
Indeed, despite the substantial difficulties in accurately
assessing pregnancy haemorrhage visually (Duthie et al,
1991) or by routine haematology (Pritchard, 1965),
a reduction in peri-partum blood loss in those with FVL
has also been suggested (Lindqvist et al, 1998, 1999). The
ABO(H) blood group system also influences haemostasis, with
group O subjects carrying a lower risk of thrombosis (Koster
et al, 1995; Clark et al, 2005), even perhaps when carrying
FVL (Gonzalez Ordonez et al, 1999; Robert et al, 2000).
Correspondingly, an influence of FVL and ABO(H) on
pregnancy-associated haemorrhage or thrombosis-linked com-
plications requires confirmation in unselected prospective
cohorts. On account of this, we examined the impact of these
two parameters in an unselected prospective cohort study of
4000 pregnancies.
Peter Clark,1 Isobel D. Walker,2 Lindsay
Govan,4 Olivia Wu3 and Ian A. Greer3
1Department of Transfusion Medicine, Ninewells
Hospital and Medical School, Dundee,
2Department of Haematology, Royal Infirmary,
Glasgow, and Departments of 3Obstetrics and
4Statistics, University of Glasgow, Glasgow, UK
Received 6 July 2007; accepted for publication
14 September 2007
Correspondence: Peter Clark, Department of
Transfusion Medicine, Ninewells Hospital and
Medical School, Dundee DD1 9SY, UK. E-mail:
peter.clark@snbts.csa.scot.nhs.uk
Summary
Factor V Leiden (FVL) and ABO(H) blood groups are the common
influences on haemostasis and retrospective studies have linked FVL with
pregnancy complications. However, only one sizeable prospective
examination has taken place. As a result, neither the impact of FVL in
unselected subjects, any interaction with ABO(H) in pregnancy, nor the
utility of screening for FVL is defined. A prospective study of 4250 unselected
pregnancies was carried out. A venous thromboembolism (VTE) rate of 1Æ23/
1000 was observed, but no significant association between FVL and pre-
eclampsia, intra-uterine growth restriction or pregnancy loss was seen. No
influence of FVL and/or ABO(H) on ante-natal bleeding or intra-partum or
postpartum haemorrhage was observed. However, FVL was associated with
birth-weights >90th centile [odds ratio (OR) 1Æ81; 95% confidence interval
(CI95) 1Æ04–3Æ31] and neonatal death (OR 14Æ79; CI95 2Æ71–80Æ74). No
association with ABO(H) alone, or any interaction between ABO(H) and
FVL was observed. We neither confirmed the protective effect of FVL on
pregnancy-related blood loss reported in previous smaller studies, nor did we
find the increased risk of some vascular complications reported in
retrospective studies.
:
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Materials and methods
The Glasgow outcome APC resistance and lipid (GOAL)
pregnancy study is a prospective examination of the impact of
FVL on pregnancy, carried out in Glasgow, Scotland between
May 1997 and February 2000. Four thousand, two hundred
and fifty unselected subjects who consecutively attended for
routine antenatal care at Glasgow Royal Maternity Hospital
were approached for recruitment, with the majority recruited
between 7 and 16 weeks gestation. Details of the recruitment,
assessment, data collection and methods of FVL assessment
used have been previously published (Clark et al, 2001).
ABO(H) phenotyping was achieved by standard serology. The
FVL laboratory results were blinded to the subjects, the
investigators and their clinicians until 6 weeks after delivery of
the index pregnancy. Ethical approval was obtained from the
local ethical committee at the Glasgow Royal Infirmary NHS
Trust, Scotland and written informed consent was obtained
from all participating subjects.
Outcomes
The definition of the outcomes recorded are as previously
reported (Clark et al, 2001). These include venous thrombo-
embolism (VTE) pregnancy-induced hypertension (PIH), pre-
eclampsia (PET), miscarriage (MISC – loss at <24 weeks),
stillbirth (SB – loss ‡24 weeks), intra-uterine growth restric-
tion (IUGR – defined at <5th centile) and neonatal death
(NND). Singleton offspring with normalized birth weights
>90th centile were also recorded. Deprivation was as assessed
by Carstairs and Morris (Morris & Carstairs, 1991; Carstairs,
1995). Visual estimation of peri-partum haemorrhage is highly
subjective and (given the rapid changes in blood volume) the
acute assessment of laboratory red cell parameters is also
unreliable (Pritchard, 1965; Duthie et al, 1991). Correspond-
ingly, we defined peri-partum haemorrhage as both (i) any
episode visually assessed as >500 ml (data not shown) and (ii)
any episode visually assessed as >500 ml which also required
clinical intervention. Such interventions for intra-partum
haemorrhage (IPH) included: additional syntometrine doses,
red cell transfusion or any form of surgical intervention.
Similarly, interventions recorded for postpartum haemorrhage
(PPH) included episodes requiring: re-admission, the admin-
istration of additional syntometrine, transfusion or any form
of surgical intervention. We also recorded all per-vaginal (PV)
bleeding episodes occurring <24 weeks, or ‡24 weeks which
also required intervention in the form of hospital admission,
additional haematinic replacement or transfusion.
Power and statistical analysis
The study was designed to examine two end-points: (i) the
impact of FVL/ABO(H) on a composite of all major vascular
complications (PET, IUGR, pregnancy loss and VTE) and (ii)
the impact of FVL/ABO(H) on peri-partum blood loss. We
assumed a combined vascular complication frequency of
13Æ6% [comprising VTE (0Æ1%) (Greer & Thomson, 2001),
PET (3%) (Walker, 2000), IUGR (5%) (Neerhof, 1995), and
pregnancy loss (‡5Æ5%) (Cashner et al, 1987; Samueloff et al,
1993)] and a peri-partum haemorrhage frequency of 8% in
non-FVL subjects. The study was designed to have >80%
power (P = 0Æ05) to detect an approximately twofold increased
risk of the composite vascular end-point in association with
FVL and also at least a 55% reduction in the occurrence of
clinically significant peri-partum haemorrhage in association
with FVL. This estimate of effect was consistent with the
50–80% reduction in per-partum haemorrhage associated with
FVL alone in previous studies (Lindqvist et al, 1998, 1999).
Unconditional logistic regression was performed to derive
odds ratios (OR), with 95% confidence intervals (CI95), for the
risk of each outcome in association with FVL, blood group
non-O (non-O compared with O), and FVL/non-O compared
with the remainder. Where appropriate, OR were also adjusted
for age, waist circumference, non-fasting lipids, parity (previ-
ous number of live births), booking diastolic blood pressure,
smoking and deprivation category. Statistical analyses were
performed using the Statistical Package for the Social Sciences
(spss) software (version 13.0 for Windows).
Results
Of the 4250 women approached, 4157 consented to partici-
pate. In the 32 women recruited twice for separate pregnancies,
data were collected from the first pregnancy only. 79 twin
pregnancies were recruited and 61 women, who gave initial
clinical data and samples, transferred to other areas or were
lost to follow-up.
The mean age (±SD) of singleton pregnancies was
28 ± 6 years, with 45Æ6% primigravid. Of these, 239 women
developed PIH, 66 developed PET, 174 experienced IUGR, 413
had a PV bleeding event <24 weeks and 366 had a PV bleeding
episode ‡24 weeks (of which 234 required additional inter-
vention). There were 50 MISC in singleton pregnancies, 22 SB
and eight NND. 304 had an IPH or PPH that required
intervention, of which 196 occurred after a non-operative
delivery. 54% of PPHs occurred £24 h of delivery. Multiple
complications were recorded in 93 women.
The characteristics of the recruits are shown (Table I).
Women who developed PET were more likely to have a waist
circumference ‡80 cm (P = 0Æ01), to be primigravid
(P < 0Æ01), to have a higher booking diastolic blood pressure
(P < 0Æ01) and less likely to be smokers (P < 0Æ01), whereas
those with IUGR were less likely to be overweight (P = 0Æ03)
and more commonly were smokers (P < 0Æ01) than pregnan-
cies with normal growth. Women with a PV bleed ‡24 weeks
were younger than those without such bleeding (P < 0Æ01).
Samples suitable for FVL analysis were available in 3944
cases, of whom 3Æ61% were carriers, with two identified as
homozygotes. Of the 3985 with appropriate samples, 47Æ6%
were non-O. OR (adjusted and unadjusted) for each outcome
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are shown (Table II). For FVL, non-significant effects were
observed for PIH, PET, IUGR, IUGR (excluding PET) and
MISC. In the multivariate regression, there was no influence of
FVL on the composite vascular outcome. Similar non-signif-
icant effects were seen when non-O were compared with group
O subjects. However, for FVL alone, significant adjusted OR
were observed for birth weights >90th centile (OR 1Æ81 CI95
1Æ04–3Æ31) and for NND (OR 14Æ79 CI95 2Æ71–80Æ74). Of the
eight NND cases, two mothers were carriers of FVL, with one
of the cases associated with a premature delivery at 23 weeks
and the other with pulmonary hypoplasia. No interaction
between FVL and non-O was observed for any outcome
(Table II). In addition, no influence of either FVL and/or
blood group non-O on the occurrence of antental PV bleeding,
IPH/PPH >500 ml (data not shown) or IPH/PPH requiring
clinical intervention was observed (Table II).
Nine subjects had had a VTE prior to the index
pregnancy. Six were non-O and two (with contraceptive-
associated VTE) carried FVL. During the index pregnancy
five experienced a VTE, three in the puerperium and two
ante-natally. None carried FVL and all, but one, were group
O. Despite this, three reported a family history of VTE in
a near relative.
Discussion
Factor V Leiden and ABO(H) blood groups are amongst the
commonest heritable influences on coagulation. In addition to
the recognized VTE risk with FVL, non-O subjects are at
a twofold increased risk of venous (Koster et al, 1995) and
perhaps arterial (Clark et al, 2005) thrombosis. This throm-
botic risk and an accompanying reduction in haemorrhage risk
in non-pregnant subjects is consistent with the influence of
ABO(H) on FVIII coagulant activity/von Willebrand factor
levels (Preston & Barr, 1964; Gill et al, 1987). Non-O has not
been examined in the context of pregnancy haemorrhage, but
has been associated with an increase in pregnancy-related VTE
(Jick et al, 1969; Larsen et al, 2005). However, any effect on the
incidence, or severity, of PET is not yet established (May, 1973;
Harlap & Davies, 1974; South & Naldrett, 1974; Sezik et al,
2002). In the non-pregnant female, the thrombotic phenotype
of FVL may be influenced by co-inheritance of non-O
(Gonzalez Ordonez et al, 1999; Robert et al, 2000; Morelli
et al, 2005), suggesting a protective effect of blood group O
against VTE. Thus, an interaction between FVL and non-O in
both thrombosis associated and haemorrhagic pregnancy
complications is plausible.
We observed a VTE rate in the index pregnancy of 1Æ23/
1000, of which 60% occurred in the early puerperium.
Although small numbers, none carried FVL and the majority
were group O. Despite this, three had a family history of VTE.
Indeed, in the whole cohort, a family history of VTE did not
increase the likelihood of FVL carriage (OR 1Æ49 CI95 0Æ9–
2Æ45), which might indicate that the addition of family history
of VTE to a selective screening strategy may not necessarilyT
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improve the identification of those with FVL, or those at risk
of FVL-linked pregnancy complications.
For those conditions (PET, IUGR and pregnancy loss) which
have been linked with thrombophilia in predominantly
retrospective studies, we found no influence of either FVL
and/or non-O. However, despite this being the largest study to
date, our study was not of sufficient size to exclude an effect on
individual complications. We did observe an increased risk of
NND in association with FVL, although both of the cases with
maternal FVL carriage had other significant abnormalities.
Intriguingly, mothers with babies >90th centile in weight were
also more likely to carry FVL (adjusted OR 1Æ81 CI95 1Æ04–
3Æ31). Although large baby size has been linked with fetal
hyper-insulinaemia and a possible increased risk of vascular
disease in the offspring (Catalano & Ehrenberg, 2006), the
exact nature of any link between high-birth weight and FVL is
unclear and requires to be confirmed as this may be a chance
observation.
We detected no effect of FVL and/or non-O on the
frequency of antenatal haemorrhage. This is, perhaps, not
surprising, given that most ante-partum haemorrhage is
considered idiopathic. Similarly, both at and after delivery,
no influence of either FVL and/or non-O on the occurrence of
any haemorrhage >500 ml or any clinically significant haem-
orrhage was observed. Although our assessment is still
relatively subjective, neither the assessment itself, nor the care
subsequently offered, is likely to have been influenced by the
knowledge of blood group or FVL status. Our results,
therefore, do not confirm previous work (Lindqvist et al,
1998), which described a beneficial influence of FVL on the
amount of visually assessed peri-partum blood loss.
Overall, our study suggests that, in routine practice,
screening of unselected subjects for FVL would not be of
value in identifying, with sufficient certainty, those at risk of
haemorrhagic or thrombosis-linked disorders to allow pre-
ventative intervention, although we did not specifically address
any potential benefit in screening family members of known
symptomatic FVL subjects.
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groups, and for those with FVL who were also non-O compared with the remainder. Results are shown for postpartum (PPH) or intrapartum
haemorrhage (IPH) requiring additional intervention for all singleton pregnancy deliveries in those not-receiving heparins (all). Results are also
shown separately for non-operative (non-op) and operative (op) singleton deliveries. Birth weights less than the 5th centile in singleton pregnancies
(intra-uterine growth restriction – IUGR <5th) in all singleton pregnancies and also excluding those with pre-eclampsia [IUGR <5th (excl. PET)] as
well as those singleton deliveries with a birth weight >90th centile (BWT >90th centile) are shown. Results are also shown for pregnancy-induced
hypertension (PIH), miscarriage (fetal loss <24 weeks gestation – MISC), still birth (fetal loss at/after 24 weeks gestation – SB), neonatal death (NND)
and for those with either a SB or NND.
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